These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19936974)

  • 21. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.
    Johnson SM; Gulhati P; Rampy BA; Han Y; Rychahou PG; Doan HQ; Weiss HL; Evers BM
    J Am Coll Surg; 2010 May; 210(5):767-76, 776-8. PubMed ID: 20421047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MTHFD1L as a folate cycle enzyme correlates with prognostic outcome and its knockdown impairs cell invasive behaviors in osteosarcoma via mediating the AKT/mTOR pathway.
    Wang L; Yang Y; Wang XM; Wang CQ; Zhang YM; Li BL
    J Recept Signal Transduct Res; 2020 Dec; 40(6):584-590. PubMed ID: 32456526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR: An attractive therapeutic target for osteosarcoma?
    Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
    Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
    Qiu Q; Jiang J; Lin L; Cheng S; Xin D; Jiang W; Shen J; Hu Z
    Int J Oncol; 2016 Jun; 48(6):2508-20. PubMed ID: 27082640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis.
    Zhan HX; Cong L; Zhao YP; Zhang TP; Chen G; Zhou L; Guo JC
    J Surg Oncol; 2012 Dec; 106(8):972-80. PubMed ID: 22711648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
    Li KW; Wang SH; Wei X; Hou YZ; Li ZH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of CLEC3A inhibits osteosarcoma cell proliferation and promotes their chemosensitivity through the AKT1/mTOR/HIF1α signaling pathway.
    Ren C; Pan R; Hou L; Wu H; Sun J; Zhang W; Tian X; Chen H
    Mol Med Rep; 2020 Apr; 21(4):1739-1748. PubMed ID: 32319617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.
    Liu D; Huang Y; Chen B; Zeng J; Guo N; Zhang S; Liu L; Xu H; Mo X; Li W
    Cancer; 2011 Aug; 117(16):3763-73. PubMed ID: 21387259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circular RNA circ-NT5C2 acts as a potential novel biomarker for prognosis of osteosarcoma.
    Nie WB; Zhao LM; Guo R; Wang MX; Ye FG
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6239-6244. PubMed ID: 30338784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma.
    Zhou Q; Zhu Y; Deng Z; Long H; Zhang S; Chen X
    Surg Oncol; 2011 Mar; 20(1):13-9. PubMed ID: 19836228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. XB130 expression in human osteosarcoma: a clinical and experimental study.
    Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
    Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Akirin2 could promote the proliferation but not the differentiation of duck myoblasts via the activation of the mTOR/p70S6K signaling pathway.
    Sun W; Huang H; Ma S; Gan X; Zhu M; Liu H; Li L; Wang J
    Int J Biochem Cell Biol; 2016 Oct; 79():298-307. PubMed ID: 27590857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome.
    Yang QC; Zeng BF; Dong Y; Shi ZM; Jiang ZM; Huang J
    Jpn J Clin Oncol; 2007 Feb; 37(2):127-34. PubMed ID: 17237146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas.
    Li XY; Zhang LQ; Zhang XG; Li X; Ren YB; Ma XY; Li XG; Wang LX
    J Neurooncol; 2011 Jul; 103(3):453-8. PubMed ID: 20878445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies.
    Lyu JW; Xu XB; Ji KQ; Zhang N; Sun Y; Zhao DD; Zhao YY; Yan CZ
    Chin Med J (Engl); 2019 Apr; 132(7):805-810. PubMed ID: 30897595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
    Liontos M; Trigka EA; Korkolopoulou P; Tzannis K; Lainakis G; Koutsoukos K; Kostouros E; Lykka M; Papandreou CN; Karavasilis V; Christodoulou C; Papatsoris A; Skolarikos A; Varkarakis I; Adamakis I; Alamanis C; Stravodimos K; Mitropoulos D; Deliveliotis C; Constantinidis CA; Saetta A; Patsouris E; Dimopoulos MΑ; Bamias A
    World J Urol; 2017 Mar; 35(3):411-419. PubMed ID: 27395374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance.
    Zhou L; Yuan D; Zhang ZG; Liang ZY; Zhou WX; Yang JY; Jiang SH; Lu J; Zhang TP; You L; Guo JC; Zhao YP
    Cancer Lett; 2017 Jun; 395():45-52. PubMed ID: 28279716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.